No Data
Report for the third quarter of 2024 of Liaoning Chengda Biology Co., Ltd.
Express News | Chengda Biotech: The application for the registration of the production of pharmaceuticals for lyophilized human rabies vaccine has been accepted.
2024 Semi-Annual Report of Liaoning Chengda Biology Co., Ltd.
Summary of the 2024 semi-annual report of Liaoning Chengda Biology Co., Ltd.
Express News | Chengda Bio: Net income in the first half of 2024 decreased by 33.99% year-on-year.
Chengda Biotech (688739.SH): The net income in the first half of the year was 0.22 billion yuan, a year-on-year decrease of 33.99%.
Gelonghui, August 29th, Chendasheng Bio(688739.SH) disclosed the semi-annual report for the year 2024. During the reporting period, the company achieved a revenue of 0.881 billion yuan, a year-on-year increase of 1.08%; net income attributable to the parent company was 0.22 billion yuan, a year-on-year decrease of 33.99%; non-GAAP net income was 0.211 billion yuan, a year-on-year decrease of 31.86%; basic earnings per share was 0.53 yuan.
No Data
No Data